Drug
GnP
GnP is a pharmaceutical drug with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_1
1
25%
Ph phase_2
1
25%
Ph phase_3
2
50%
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting3
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)
Trials by Status
not_yet_recruiting125%
recruiting375%
Recent Activity
3 active trials
Showing 4 of 4
recruitingphase_3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152
recruitingphase_1
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT06835569
not_yet_recruitingphase_3
A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)
NCT07336953
recruitingphase_2
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
NCT05268692
Clinical Trials (4)
Showing 4 of 4 trials
NCT07562152Phase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT06835569Phase 1
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT07336953Phase 3
A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)
NCT05268692Phase 2
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4